Compare Enbridge Inc (ENB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs 10X Genomics Inc — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Enbridge Inc is far larger — about 10.3× 10X Genomics Inc's market cap, and Enbridge Inc pays a 6.02% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and 10X Genomics Inc for 91 Days on average.
| ENB | TXG | |
|---|---|---|
Market Cap | $103.38B | $10.07B |
Volume | 3,684,305 | 5,657,286 |
Sector | Energy | Health |
52-Week High | $58.04 | $97.74 |
52-Week Low | $45.23 | $11.48 |
Typical Hold Time | 91 Days | 91 Days |
Enterprise Value | $185.39B | $9.59B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.54, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.19B in 2025, and the dividend yield is attractive at approximately 6% based on the recent $0.97 payout. Analyst consensus is mixed with a $61.63 price target, indicating potential upside from current levels.
The outlook for ENB is supported by stable cash flows and a secured project backlog, but risks include high debt levels and sensitivity to interest rates. Investment opportunity lies in the dividend income and valuation discount to analyst targets, though investors face headwinds from energy market volatility and rising leverage.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
